A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

228

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG

QLS32015

QLS32015 will be administered subcutaneously.

DRUG

Pomalidomide

Pomalidomide will be administered orally.

DRUG

Selinexor

Selinexor will be administered orally.

DRUG

Dexamethasone

Dexamethasone will be administered orally

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY